Bevacizumab, an anti–vascular endothelial growth factor treatment for which 1 biosimilar has been approved to date, has been shown to improve quality of life for patients with glioblastoma—and to delay disease progression—but has not prolonged patients’ overall survival. However, recent research suggests that using 4 older drugs together with bevacizumab could provide a more effective treatment protocol.
Bevacizumab, an anti—vascular endothelial growth factor (anti-VEGF) treatment for which 1 biosimilar has been approved to date, has been shown to improve quality of life for patients with glioblastoma—and to delay disease progression—but has not prolonged patients’ overall survival.
However, recent research suggests that using 4 older drugs together with bevacizumab could provide a more effective treatment protocol. Writing in Medical Sciences, Richard E. Kast, MD, describes the current research supporting this regimen.
The drugs in question are apremilast, which treats psoriasis; dapsone, an antibiotic that treats Hansen disease; zonisamide, which treats seizures; and telmisartan, which treats hypertension.
Using these drugs in combination with bevacizumab is expected to lower intracranial pressure, allow for steroid-sparing treatment, enhance bevacizumab’s effects, provide synergy with temozolomide, exert anti-glioma effects, and have low risk of adverse events.
All of these drugs, writes Kast, are low-risk drugs when they are used individually, and are all relatively inexpensive and widely available. Phase 3 testing of the regimen will be necessary prior to general use, however.
Reference
Kast RE. Paths for improving bevacizumab available in 2018: the ADZT regimen for better glioblastoma treatment. Med Sci. 2018;6(4); 84. doi:10.3390/medsci6040084.
How AI Can Help Address Cost-Related Nonadherence to Biologic, Biosimilar Treatment
March 9th 2025Despite saving billions, biosimilars still account for only a small share of the biologics market—what's standing in the way of broader adoption and how can artificial intelligence (AI) help change that?
Eye on Pharma: Keytruda Biosimilar Deal; German Court Bans Imraldi; New Biosimilars for Japan
June 17th 2025Alvotech and Dr. Reddy's partner to develop a Keytruda biosimilar, a German court bans Humira biosimilar over patent dispute, and Samsung Bioepis enters a strategic agreement with NIPRO Corporation in Japan.
Will the FTC Be More PBM-Friendly Under a Second Trump Administration?
February 23rd 2025On this episode of Not So Different, we explore the Federal Trade Commission’s (FTC) second interim report on pharmacy benefit managers (PBMs) with Joe Wisniewski from Turquoise Health, discussing key issues like preferential reimbursement, drug pricing transparency, biosimilars, shifting regulations, and how a second Trump administration could reshape PBM practices.